A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Clascoterone (Winlevi)

Androgen Receptor Inhibitor class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2021-10-04
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$1.7M in CY2024 Part D spend3K claims · 1K beneficiaries · 329 plans surveyed

Lowest NADAC
$9.99/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$9.99
Across all dosage forms in distribution.
Highest NADAC
$9.99
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Clascoterone used for?

Clascoterone is a Androgen Receptor Inhibitor medication tracked in Medicare Part D.

Is there a generic for Clascoterone?

No. Clascoterone is brand-only with no generic equivalents currently in market.

How much does my plan pay for Clascoterone?

Across 329 Part D plans, Clascoterone averages $9.99/unit (NADAC). Lowest available: $9.99/unit. Highest in distribution: $9.99/unit.

Is Clascoterone on the FDA shortage list?

No. Clascoterone is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Androgen Receptor Inhibitor4 alternatives in D1
01
Bicalutamide
Brand: CASODEX
$0.403Lowest NADAC
6Generic mfrs
$10.9MCY24 Part D spend
Compare →
02
Enzalutamide
Brand: Xtandi
Lowest NADAC
0Generic mfrs
$5.84BCY24 Part D spend
Compare →
03
Flutamide
Brand: Eulexin
Lowest NADAC
1Generic mfrs
$216,500CY24 Part D spend
Compare →
04
Nilutamide
Brand: Nilandron
Lowest NADAC
1Generic mfrs
$1.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.